Nurix enrolls first patient in bexobrutideg combination trial for CLL
Nurix Therapeutics enrolled the first patient in its Phase 1b/2 NX-5948-203 trial of bexobrutideg with venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. The Roche collaboration study will assess safety, tolerability and clinical activity, initially in relapsed or refractory CLL. Nurix said the program could later include previously untreated CLL and combinations with Roche's anti-CD20 antibodies.
Why it matters
The enrollment starts clinical testing of Nurix's combination regimen with venetoclax. Nurix expects trial data to guide potential registration plans across CLL treatment settings and possible development in other B-cell cancers.
Key facts
- 1Nurix enrolled the first participant in the Phase 1b/2 NX-5948-203 study of bexobrutideg plus venetoclax. globenewswire.com
- 2The initial study cohort is for relapsed or refractory CLL, with possible expansion into first-line CLL. globenewswire.com
- 3The trial is conducted through Nurix's global collaboration with Roche. globenewswire.com
- 4NX-5948-203 carries the clinical-trial identifier NCT07520006. globenewswire.com
- 5The study will evaluate safety, tolerability and clinical activity of the drug combination. investing.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.